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loci (P40.05; Supplementary Table S4
online), suggesting that these SNPs act
independently of FLG-null mutations
towards the contribution of atopic
disease. However, we note that our
power to detect interaction may be
limited by insufficient sample numbers
(Purcell et al., 2003).
In summary, our findings validate
a strong association at chr10q21.2 and
a weaker one at 20q13.33 with AD
among Singaporean Chinese subjects,
but suggests that genetic association at
5q22.1 might be influenced by the
interaction with environmental factors.
The identification of new validated AD
loci is important to further dissect the
genetic basis of this complex disease
and account for the large number of
AD cases that do not have FLG-null
mutations. Clinically this is also vital as
more genome-targeted therapies are
developed.
URLs
Genetic Power Calculator: http://pngu.
mgh.harvard.edu/~purcell/gpc/
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TO THE EDITOR
A key event during epidermal differen-
tiation is the proteolytic breakdown of
profilaggrin into ‘‘free’’ filaggrin mono-
mers. A recent study has shown that
the skin-specific retroviral-like aspartic
protease (SASPase) has a key role in
profilaggrin–filaggrin processing (Matsui
et al., 2011). SASPase cleaves the linker
peptide between the individual filag-
grin monomers of profilaggrin, and
on a hairless mouse background loss
of SASPase leads to dry, scaly skin with
reduced stratum corneum hydration
accompanied by accumulations of pro-
filaggrin–filaggrin intermediates but an
absence of filaggrin monomers (MatsuiAbbreviations: ASPRV1, SASPase gene; SASPase, skin-specific retroviral-like aspartic protease
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et al., 2011). In this same study, several
missense mutations in the SASPase
gene in atopic eczema patients and
controls were identified, some of which
were shown to have a detrimental effect
on the ability of SASPase to cleave the
profilaggrin linker peptide. Given the
important role of filaggrin in skin barrier
function and maintaining stratum cor-
neum hydration (O’Regan and Irvine,
2010), these results prompted us to
question whether aberrant profilag-
grin–filaggrin processing due to altered
SASPase activity could provide an
alternative pathogenic mechanism for
atopic eczema or clinically dry skin.
To answer this question, the entire
coding region of the SASPase gene,
ASPRV1, was amplified by PCR in
a single fragment and fully sequenced.
To maximize our chances of finding
mutations that might be associated
with atopic eczema or clinically dry
skin, we sequenced ASPRV1 from three
discovery cohorts; 96 pediatric atopic
eczema cases from Ireland, 96 atopic
eczema cases from the Cape Town
region of South Africa (Xhosa people),
and 99 cases of clinically dry skin from
patients referred to dermatology clinics
in Glasgow, Scotland. Atopic eczema
in the Irish pediatric cases was diag-
nosed using the UK Diagnostic criteria
(Williams et al., 1994); atopic eczema
in the Xhosa people was diagnosed by
experienced dermatologists. Clinically
dry skin was defined using a previously
published scoring system (Sergeant
et al., 2009). Demographic and clinical
data relating to the discovery cohorts
are shown in Table 1.
Sequencing of the ASPRV1 gene in
the discovery cohorts identified a total
of five non-synonymous mutations and
two synonymous mutations (Table 2).
None of the ASPRV1 mutations iden-
tified in a previous Japanese study
(Matsui et al., 2011) were detected in
our discovery cohorts. We then inves-
tigated some of these mutations further
by screening an additional 259 Irish
atopic eczema cases and 167 Scottish
dry skin cases (which included the
original 93 cases from the discovery
cohort) using custom-designed TaqMan
allelic discrimination assays for the
mutations V74I, G87R, and S333F
Table 1. Demographic and clinical data relating to eczema and dry skin cases and population controls
Demographic and clinical features
South African atopic
eczema cases
Irish atopic
eczema cases
Irish population
controls
Scottish dry
skin cases
Scottish population
controls
Total number (% male) 102 (51.0) 442 (63.6) 460 (30.7) 178 (34.8) 100 (50.0)
Age in years, mean (SD) and range 8.9 (9.9) 3.3 (11.8) 35.4 (9.2) 45.5 (48.1) X18
0.7–50.9 0.25–17.0 19–69 18–86
Eczema severity score, mean (SD) and range 10.4 (2.7) 11.3 (6.4) 0 NA NA
5–15 3–15
Reported childhood eczema (%) NA NA NA 16.3 NA
Abbreviations: NA, not applicable; SD, standard deviation.
All patient studies conformed to the Declaration of Helsinki Principles, and written informed consent was obtained. Irish population controls represent
healthy adults from the population-based Trinity Biobank control samples; Scottish population controls are derived from adults attending hospital for
hematological investigations; eczema severity is scored using the Nottingham Eczema Severity Score (Emerson et al., 2000); dry skin was defined using a
previously reported scoring system (Sergeant et al., 2009) and corresponds to visible fine scale (noted by a trained observer) on one/more body sites, self-
reported use of a moisturizer more than once weekly, or self-reported dry skin ‘‘moderately’’ to ‘‘a lot’’.
Table 2. dbSNP minor allele frequencies of ASPRV1 polymorphisms identified in the discovery cohorts
ASPRV1 mutation
dbSNP minor
allele rs number
Irish atopic eczema
cases (n=92)
South African atopic
eczema cases (n=90)
Scottish dry skin
cases (n=93)
c.145 A4G1 p.T49A A rs3796097 A=0.418 A=0.083 A=0.435
c.155 G4A p.R52Q NA rs151323610 A=0.005 0 0
c.220 G4A p.V74I A=0.005 0 0
c.259 G4A p.G87R NA rs148290351 0 0 A=0.005
c.618 C4T p.P206P T rs114182672 0 T=0.005 0
c.973 C4T p.L325 L T rs115036001 0 T=0.111 0
c.998 C4T p.S333F 0 0 T=0.005
Abbreviations: dbSNP, Single-Nucleotide Polymorphism Database; n, the number of fully sequenced samples, NA, minor allele not ascertained.
1G is the ancestral allele and A is the designated minor allele for this mutation.The ASPRV1 gene was amplified for sequencing using forward primer
50-ATGTGGTAGGAGCTCAGTACATGTAAAC-30 and reverse primer 50-AGAAGAGCAAGAGTTGATAAGCAGACTG-30 to generate a 1,532-bp product.
50 ng of genomic DNA was amplified in a 25ml reaction using 0.5 U AmpliTaq Gold polymerase (Applied Biosystems). For PCR amplification, an annealing
temperature of 651C and a 3 minute extension at 721C was used (35 cycles). PCR products were purified and sequenced using overlapping primers in both
directions: Forward 1 50-TTCCTTCACTGGCTGATGAC-30; Forward 2 50-TTGCTGCTGAGGTTCCAGAG-30; Forward 3 50-TCACTGATGGCGATCTGGAC-30
and Reverse 1 50-AGAAGAGCAAGAGTTGATAAGC-30; Reverse 2 50-CCCAGGATCTTCATTTCAGC-30 Reverse 3 50-GATGACTTCAAAGCTGTGCAG-30.
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(Supplementary Table S1 online). The
G87R mutation was identified only in
a single case of atopic eczema, and
the V74I and S333F mutations were
not detected in any of these additional
cases. In the 167 cases of dry skin, the
G87R and S333F mutations were found
only in single cases (i.e., in the original
discovery cohort) and the V74I muta-
tion was not found in any of the cases.
We then carried out two independent
case–control studies to investigate any
association between the T49A mutation
and atopic eczema and clinically dry
skin (Supplementary Table S2 online).
Overall, 442 Irish atopic eczema cases
(which included the original 92 cases
from the discovery cohort) and 458 Irish
population controls were screened
using a TaqMan allelic discrimination
assay. There was no association bet-
ween the T49A mutation and atopic
eczema in the Irish study: w2-test
P¼0.415, odds ratio¼0.98 (95% con-
fidence interval 0.81–1.18). Similarly,
screening of 167 clinically dry skin
cases and 100 Scottish population
controls failed to reveal any association
between the T49A mutation and
dry skin: P¼0.479, odds ratio¼0.90
(0.63–1.28). Power calculations showed
that the eczema case–control study had
480% power to detect an odds ratio of
1.5 or above and the dry skin case–
control study had 470% power to
detect an odds ratio of 2.0 (Quanto
1.2.4, University of Southern California,
http://hydra.usc.edu/gxe/). As FLG-null
mutations are known to have such a
strong effect on eczema risk, it is possi-
ble that the effect of ASPRV1 mutations
may only be apparent in FLG wild-type
individuals. Therefore, the four most
prevalent FLG-null mutations (R501X,
2282del4, R2447X, and S3247X) were
screened in each of the cases and
controls using methods described pre-
viously (Sandilands et al., 2007; Kezic
et al., 2011). The statistical analyses for
each study were repeated after exclud-
ing individuals carrying FLG-null muta-
tions, but there was still no evidence of
association between ASPRV1 mutation
T49A and eczema or clinically dry skin
(Supplementary Table S3 online).
With the exception of T49A and
to a lesser extent L325L, the remaining
ASPRV1 mutations that we identified
were rare (o1%) and therefore unlikely
to be significant on a population level,
although it is still possible that these
rare mutations could contribute signi-
ficantly to individual disease risk.
Mutations P206P and L325L result in
synonymous changes and are there-
fore unlikely to be pathogenic. All of
the non-synonymous mutations we
identified (Supplementary Figure S1
online) affect amino acid residues out-
side the active protease site of SASPase
(Bernard et al., 2005); however, the effect
of these mutations on SASPase activity
remains to be determined experimentally.
Finally, we used custom-designed
TaqMan allelic discrimination assays
(Supplementary Table S1 online) to
screen for the V187I and V243A muta-
tions, which reduce and abolish SAS-
Pase-mediated profilaggrin cleavage,
respectively (Matsui et al., 2011). How-
ever, we failed to detect these muta-
tions in any of the discovery cohorts,
nor in the Irish atopic eczema cohort,
indicating that these mutations are
likely to be specific to the Japanese
population.
Although our results failed to find
an association between ASPRV1 gene
mutations and atopic eczema or clini-
cally dry skin in the European popula-
tions that we studied, they do not
exclude the possibility that an asso-
ciation exists in other ethnicities. In
the populations that we studied, other
factors that modulate SASPase activity
could contribute instead, such as the
actions of protease inhibitors that pro-
vide a powerful counterbalance against
excessive protease activities (Hewett
et al., 2005). Profilaggrin-filaggrin pro-
cessing is a tightly regulated process
involving not just SASPase but multiple
proteases such as elastase 2 (Bonnart
et al. 2010) and the serine proteases
matriptase/MT-SP1 (List et al., 2003)
and prostasin (Leyvraz et al., 2005). A
greater understanding of the proteases
and inhibitors involved in profilaggrin-
filaggrin processing will be required to
fully appreciate their contribution to
skin barrier dysfunction.
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TO THE EDITOR
The vascular contribution to the
pathogenesis of psoriasis has generally
received limited attention, although
abnormalities in cutaneous vessels
in psoriatic lesions are a prominent
feature. The dermal blood vessels in
psoriatic lesions are found to be tor-
tuous, enlarged, and hyperpermeable
(Creamer et al., 2002; Heidenreich
et al., 2009). Interestingly, these micro-
vascular changes occur very early in
the development of the psoriatic lesion,
suggesting that angiogenesis is one of
the key features of psoriasis patho-
genesis (Creamer et al., 2002). In
1994, vascular endothelial growth
factor (VEGF) was identified as a major
epidermis-derived growth factor that
was strongly upregulated in skin lesions
of psoriasis (Detmar et al., 1994).
Previous studies have demonstrated
increased serum levels of VEGF in
psoriasis patients that correlated to
disease severity (Creamer et al., 1996;
Nielsen et al., 2002; Heidenreich et al.,
2009). Recently, serum levels of VEGF
and its soluble receptor sVEGFR1 were
significantly increased in psoriasis, with
the highest levels in patients with a
psoriasis area and severity index score
higher than 20 (Flisiak et al., 2008). In
contrast, we and others have demon-
strated no significant increase in VEGF
serum levels in patients with mild-to-
moderate psoriasis (Barile et al., 2006;
Anderson et al., 2010). Moreover, VEGF-
overexpressing transgenic mice displayed
an increased density of tortuous capil-
laries and were shown spontaneously to
develop an inflammatory skin disorder
resembling psoriasis (Xia et al., 2003).
The increasing evidence for the role
of VEGF in the pathogenesis of psori-
asis has led to interest in VEGF as a
modifier gene in psoriasis. Certain
genetic variants of VEGF may repre-
sent an ‘‘angiogenic constitution’’ with
an increased risk of developing psori-
asis. In line with this hypothesis, recent
studies have indicated that distinct
single-nucleotide polymorphisms (SNPs)
in the VEGF gene are linked with reduced
or increased expression levels (Watson
et al., 2000; Stevens et al., 2003).
In a large and well-defined family-
based patient sample, we have aimed
comprehensively to characterize vari-
ations throughout the VEGF gene.
Haplotype-tagging SNPs were selected
for genotyping from a 19.7 kb region
using the HapMap release 27 data
(www.hapmap.org) and the Tagger
utility of Haploview (www.broad.mit.
edu/mpg/tagger). The 19.7 kb region
r 2= 0.97
r 2= 0.9
– 634 G>C
405 G>C
rs2010963
– 460 C>T
rs833061
PROMOTOR 5′-UTR CDS CDS CDS 3′-UTRINTRON2
INTRON
5
rs833068 rs833070 rs3025010 rs10434* * * *
1612 G>A
Figure 1. Structure of the VEGFA gene and the positions of the tSNPs analyzed in this study. tSNP, tag
single-nucleotide polymorphism; UTR, untranslational region.
Abbreviations: SNP, single-nucleotide polymorphism; VEGF, vascular endothelial growth factor
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